At the Microbiome Times Partnering Forum, Massimo Marzorati, CEO of ProDigest, presents “The Selection of a Pre-Clinical Model is Driven by the Specific Research Question”. A talk highlighting the company’s expertise in simulating the gastrointestinal (GI) tract using best-in-class in vitro technologies such as SHIME®, Colon-on-a-plate®, and Diamod®. Designed to support product development in food, feed, and pharma, these platforms replicate digestive processes and host-microbiota interactions under physiologically relevant conditions.
Key drivers explored include the 3Rs (reduce, refine, replace) in animal research, the growing need for personalization in nutrition and medicine, and the balance between mechanistic depth and experimental throughput. Through real-world case studies, the talk demonstrates how ProDigest tailors model selection- ranging from high-throughput to long-term dynamic simulations – based on research questions such as digestion, microbiota modulation, compound fermentation, and gut barrier function.
With technologies validated against in vivo outcomes and adaptable to different health and disease populations, ProDigest offers a robust, ethical, and scalable approach to de-risking early-stage product development through mechanistic insight into gut-related activity.